# Treatment of GLP-1 for Diabetic Bariatric Patients

> **NCT04624672** · PHASE4 · TERMINATED · sponsor: **Geisinger Clinic** · enrollment: 3 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide (1 Mg Dose)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04624672
- **Lead sponsor:** Geisinger Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-25
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-08-17
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2023-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624672, "Treatment of GLP-1 for Diabetic Bariatric Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04624672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*